Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Nov;47(11):1257-66.
doi: 10.1007/s00535-012-0585-0. Epub 2012 May 9.

Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease

Affiliations
Clinical Trial

Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease

Tadashi Ikegami et al. J Gastroenterol. 2012 Nov.

Abstract

Background: This study is a post-hoc analysis of a subset of patients who participated in our multi-institutional case-control study that evaluated the effects of pitavastatin in patients with non-alcoholic fatty liver disease (NAFLD) with hypercholesterolemia.

Methods: Serum samples of fifteen patients with biopsy-proven NAFLD with dyslipidemia were investigated. Serum markers of lipid metabolism were quantified by liquid chromatography-mass spectrometry (LC-MS)/MS. These data were then compared with those of 36 sex- and age-matched healthy controls. In addition, changes in these markers produced by treatment with pitavastatin were evaluated.

Results: Serum non-cholesterol sterols, reflecting intestinal cholesterol absorption, were significantly lower in the NAFLD patients compared to the controls, and the cholesterol synthesis marker, the ratio of lathosterol to cholesterol, was not significantly different between the two groups. Serum proportions of liver X receptor α (LXRα) ligand oxysterols (ratios to cholesterol) were significantly elevated in the NAFLD patients compared to the controls. The sum of oxysterols relative to cholesterol and the homeostasis model assessment as an index of insulin resistance (HOMA-IR) were significantly correlated. The marker representing cholesterol synthesis was significantly suppressed by pitavastatin treatment, from 3 months after initiation of the treatment, and the suppression remained significant during the observation period. The markers representing cholesterol absorption were unchanged at 3 months, but had significantly increased at 12 months. Serum oxysterol levels relative to cholesterol maintained high values and did not change significantly during the 12-month period of treatment.

Conclusions: We speculate that serum LXRα ligand oxysterol levels (relative to cholesterol) could be surrogate markers of insulin resistance, and that high oxysterol levels in the circulation may play an important role in the development of hepatic and peripheral insulin resistance followed by NAFLD.

PubMed Disclaimer

References

    1. J Lipid Res. 2011 Aug;52(8):1509-16 - PubMed
    1. Science. 2004 Feb 20;303(5661):1201-4 - PubMed
    1. J Clin Invest. 2002 Sep;110(5):671-80 - PubMed
    1. J Lipid Res. 2009 Oct;50(10):2124-30 - PubMed
    1. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7238-43 - PubMed

Publication types

MeSH terms

LinkOut - more resources